Nuveen’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.7M | Sell |
982,353
-290,996
| -23% | -$3.63M | ﹤0.01% | 1508 |
|
|
2025
Q4 | $16.5M | Sell |
1,273,349
-434,493
| -25% | -$5.58M | ﹤0.01% | 1262 |
|
|
2025
Q3 | $22.1M | Buy |
1,707,842
+681,404
| +66% | +$9.1M | 0.01% | 1087 |
|
|
2025
Q2 | $18.3M | Buy |
1,026,438
+332,670
| +48% | +$5.8M | 0.01% | 1158 |
|
|
2025
Q1 | $12.4M | Buy |
693,768
+334,816
| +93% | +$7.6M | ﹤0.01% | 1425 |
|
|
2024
Q4 | $10.7M | Sell |
358,952
-5,601
| -2% | -$119K | ﹤0.01% | 1564 |
|
|
2024
Q3 | $5.7M | Sell |
364,553
-79,146
| -18% | -$1.44M | ﹤0.01% | 1922 |
|
|
2024
Q2 | $7.6M | Buy |
443,699
+154,590
| +53% | +$2.72M | ﹤0.01% | 1739 |
|
|
2024
Q1 | $4.52M | Sell |
289,109
-23,570
| -8% | -$347K | ﹤0.01% | 2041 |
|
|
2023
Q4 | $4.67M | Sell |
312,679
-15,981
| -5% | -$214K | ﹤0.01% | 2022 |
|
|
2023
Q3 | $5.31M | Buy |
328,660
+31,894
| +11% | +$920K | ﹤0.01% | 1834 |
|
|
2023
Q2 | $12.3M | Sell |
296,766
-4,616
| -2% | -$287K | ﹤0.01% | 1377 |
|
|
2023
Q1 | $18.1M | Sell |
301,382
-375
| -0.1% | -$30K | 0.01% | 1109 |
|
|
2022
Q4 | $22.1M | Sell |
301,757
-62,259
| -17% | -$4.68M | 0.01% | 970 |
|
|
2022
Q3 | $27.7M | Buy |
364,016
+10,224
| +3% | +$798K | 0.01% | 817 |
|
|
2022
Q2 | $24.6M | Sell |
353,792
-6,633
| -2% | -$500K | 0.01% | 905 |
|
|
2022
Q1 | $28.3M | Sell |
360,425
-296
| -0.1% | -$21.8K | 0.01% | 964 |
|
|
2021
Q4 | $27.1M | Sell |
360,721
-39,907
| -10% | -$4.01M | 0.01% | 1046 |
|
|
2021
Q3 | $46.5M | Sell |
400,628
-90,203
| -18% | -$13.6M | 0.01% | 722 |
|
|
2021
Q2 | $109M | Buy |
490,831
+20,043
| +4% | +$3.9M | 0.03% | 447 |
|
|
2021
Q1 | $62.2M | Sell |
470,788
-17,269
| -4% | -$2.73M | 0.02% | 626 |
|
|
2020
Q4 | $84.5M | Buy |
488,057
+133,149
| +38% | +$18.2M | 0.03% | 482 |
|
|
2020
Q3 | $39.5M | Buy |
354,908
+108,073
| +44% | +$8.64M | 0.02% | 673 |
|
|
2020
Q2 | $14.6M | Sell |
246,835
-318,704
| -56% | -$21M | 0.01% | 1237 |
|
|
2020
Q1 | $38.1M | Buy |
565,539
+87,328
| +18% | +$6.9M | 0.02% | 588 |
|
|
2019
Q4 | $40.3M | Sell |
478,211
-6,785
| -1% | -$548K | 0.02% | 783 |
|
|
2019
Q3 | $36.3M | Sell |
484,996
-23,176
| -5% | -$1.85M | 0.01% | 822 |
|
|
2019
Q2 | $30.9M | Buy |
508,172
+483,912
| +1,995% | +$24.5M | 0.01% | 922 |
|
|
2019
Q1 | $1.17M | Sell |
24,260
-217,468
| -90% | -$10.5M | 0.01% | 716 |
|
|
2018
Q4 | $8.09M | Sell |
241,728
-173,182
| -42% | -$6.33M | 0.05% | 423 |
|
|
2018
Q3 | $21.7M | Sell |
414,910
-21,775
| -5% | -$867K | 0.12% | 281 |
|
|
2018
Q2 | $13.7M | Buy |
436,685
+138,257
| +46% | +$3.85M | 0.09% | 333 |
|
|
2018
Q1 | $6.51M | Buy |
+298,428
| New | +$6.42M | 0.04% | 446 |
|
Other funds holding NVCR
SCM
VPM
VCM
QCM
Nuveen's NVCR Position: Q1 2026 in Review
Nuveen reduced its NovoCure (NVCR) stake by 23% in Q1 2026, selling an estimated $3.63M and leaving 982,353 shares worth $10.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1508.
Nuveen first reported a position in NVCR in Q1 2018 and has held it in 33 quarters since. The position peaked at $109M in Q2 2021. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.
- Nuveen held 982,353 shares of NovoCure worth $10.7M as of Q1 2026.
- Nuveen sold 290,996 NovoCure shares in Q1 2026, an estimated $3.63M.
- NovoCure made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1508 holding.
- Nuveen first reported a position in NovoCure in Q1 2018 and has held it in 33 quarters since.
- Nuveen's NovoCure position peaked at $109M in Q2 2021.
- 223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.
Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.